MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco.2007.15.9319

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2008

Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma.

Lacy Martha Q, Alsina Melissa, Fonseca Rafael, Paccagnella M Luisa, Melvin Carrie L, Yin Donghua, Sharma Amarnath, Enriquez Sarano M, Pollak Michael, Jagannath Sundar, Richardson Paul, Gualberto Antonio

Клиническое исследование I фазыСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

PURPOSE: A phase I first-in-human study was conducted to characterize the safety, tolerability, pharmacokinetic, and pharmacodynamic properties of the anti-insulinlike growth factor 1 receptor (IGF-IR) monoclonal antibody CP-751,871.

PATIENTS AND

METHODS

After informed consent and screening, 47 patients with multiple myeloma in relapse or refractory phase were enrolled into 11 dose-escalation cohorts of CP-751,871 at doses from 0.025 to 20 mg/kg for 4 weeks. Patients with less than a partial response to CP-751,871 treatment were eligible to receive CP-751,871 in combination with oral dexamethasone at the discretion of the investigator. Treatment with CP-751,871 and rapamycin with or without dexamethasone was also offered to patients enrolled in the 10 and 20 mg/kg cohorts with less than a partial response to initial therapy with single-agent CP-751,871.

RESULTS

No CP-751,871-related dose-limiting toxicities were identified. Plasma CP-751,871 concentrations increased with dose and concentration-time profiles were consistent with those of antibodies with target-mediated disposition. Importantly, CP-751,871 administration led to a decrease in granulocyte IGF-IR expression and serum insulinlike growth factor 1 accumulation at high doses, suggesting systemic IGF-IR inhibition. Tumor response was assessed according to the European Group for Blood and Marrow Transplantation criteria. Nine responses were reported in 27 patients treated with CP-751,871 in combination with dexamethasone. Of interest, two of the patients with a partial response were progressing from dexamethasone treatment at study entry.

CONCLUSION

These data indicate that CP-751,871 is well tolerated and may constitute a novel agent in the treatment of multiple myeloma.

Для цитирования: Lacy Martha Q, Alsina Melissa, Fonseca Rafael, Paccagnella M Luisa, Melvin Carrie L, Yin Donghua, Sharma Amarnath, Enriquez Sarano M, Pollak Michael, Jagannath Sundar, Richardson Paul, Gualberto Antonio. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008. DOI: 10.1200/jco.2007.15.9319.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.